Anthem Biosciences Lists at 26.7% Premium
By Ankur Chandra | Updated at: Jan 7, 2026 02:50 PM IST
Mumbai, July 21, 2025 – Shares of Anthem Biosciences Limited made a strong debut on the stock exchanges today, listing at ₹723.05 on the NSE against the IPO price of ₹570, marking a listing premium of 26.7%. The stock surged further to hit ₹747. The Bengaluru-based company’s IPO saw more than 67 times subscription.
Listing Day Trade Snapshot
As of 11:39 IST on July 21, Anthem Biosciences traded at ₹725.45, up 27.27% from its IPO price. The volume stood at 313.63 lakh shares with a turnover of ₹2,289.65 crore and VWAP at ₹730.06.
| Parameter | Data |
|---|---|
| Listing Price | ₹723.05 |
| Day’s High | ₹747.00 |
| Day’s Low | ₹723.05 |
| Current Price | ₹725.45 (+₹155.45) |
| % Change from Issue Price | +27.27% |
| Traded Volume | 313.63 lakh shares |
| Traded Value | ₹2,289.65 crore |
| Market Cap | ₹40,733.58 crore |
| Buy Quantity | 27,65,901 |
| Sell Quantity | 42,10,511 |
| 52-Week Range (Debut Day) | ₹723.05 – ₹747.00 |
| Applicable Margin Rate | 12.50% |
| Face Value | ₹2 |
Strong Start Reflects IPO Momentum
The strong listing comes on the back of a robust IPO response:
- QIBs subscribed 192.80 times
- NIIs subscribed 44.70 times
- Retail subscribed 5.98 times
- Employees subscribed 6.99 times
- Total subscription stood at 67.42 times
The aggressive bidding and investor interest were driven by Anthem’s positioning as a full-service Contract Research, Development and Manufacturing Organization (CRDMO) with global clientele, differentiated capabilities across modalities, and consistent financial performance.
What’s Next?
Following the positive debut, investor focus will now shift to:
- Listing day closing performance
- Institutional buying activity
- Quarterly results and post-IPO guidance
Market analysts are expected to track the stock’s movement closely, especially as it continues to trade with high volumes and wide retail interest.
Outlook
A strong debut backed by oversubscription and global CRDMO positioning signals market confidence in Anthem’s growth visibility. High trading volumes and retail interest suggest sustained near-term activity, while upcoming earnings and post-IPO execution will determine valuation durability.
About Anthem Biosciences
Anthem Biosciences Limited, headquartered in Bengaluru, is one of India’s fastest-growing CRDMOs with expertise across drug discovery, development, and manufacturing. Its capabilities span small and large molecule development, including RNAi, ADCs, peptides, lipids, and oligonucleotides. The company operates multiple state-of-the-art manufacturing units in Karnataka and serves clients globally across North America, Europe, and Asia.
REF: https://www.nseindia.com/get-quotes/equity?symbol=ANTHEM
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
